Actinogen extends cash runway as pivotal Alzheimer’s trial advances

Actinogen Medical ( (AU:ACW) ) has provided an announcement.

Actinogen Medical reported steady progress in its pivotal XanaMIA phase 2b/3 Alzheimer’s disease trial, with an independent data monitoring committee recommending the study continue unchanged after a positive interim analysis, and topline results expected in November 2026. The company has also launched an open‑label extension to provide long‑term access to Xanamem and gather extended safety and efficacy data to support future regulatory submissions.

The biotech strengthened its balance sheet with a $16.8 million capital raising, a $7.3 million annual research and development tax incentive rebate, and $4.3 million in non‑dilutive funding, ending the March quarter with $21.5 million in cash and runway beyond the XanaMIA readout. Actinogen is advancing commercial planning and regulatory strategy, including preparing for a second pivotal Alzheimer’s trial and exploring the U.S. FDA’s flexibility on single pivotal trials, positioning the company for potential early marketing approval if upcoming results are favorable.

The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical is an Australian biotechnology company focused on developing therapies for neurological disorders, particularly Alzheimer’s disease. Its lead candidate, Xanamem, is being advanced through late-stage clinical trials targeting cognitive decline, with a primary market focus on dementia-related indications in Australia and the U.S.

Average Trading Volume: 3,459,506

Technical Sentiment Signal: Hold

Current Market Cap: A$158M

Learn more about ACW stock on TipRanks’ Stock Analysis page.